RANI THERAPEUTICS HOLDINGS-A (RANI)
US7530181004 - Common Stock
Overall RANI gets a fundamental rating of 1 out of 10. We evaluated RANI against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of RANI have multiple concerns. RANI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year RANI has reported negative net income.
In the past year RANI has reported a negative cash flow from operations.
In the past 5 years RANI always reported negative net income.
RANI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RANI's Return On Assets of -58.65% is on the low side compared to the rest of the industry. RANI is outperformed by 62.05% of its industry peers.
With a Return On Equity value of -264.01%, RANI is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.65% | ||
| ROE | -264.01% | ||
| ROIC | N/A |
ROA(3y)-31.23%
ROA(5y)-46.07%
ROE(3y)-121.5%
ROE(5y)-105.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for RANI has been reduced compared to 1 year ago.
The debt/assets ratio for RANI is higher compared to a year ago.
2.2 Solvency
RANI has an Altman-Z score of -0.38. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
RANI has a Altman-Z score (-0.38) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.90 is on the high side and indicates that RANI has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.90, RANI is doing worse than 80.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.9 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.38 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.36 indicates that RANI has no problem at all paying its short term obligations.
RANI's Current ratio of 6.36 is fine compared to the rest of the industry. RANI outperforms 74.87% of its industry peers.
A Quick Ratio of 6.36 indicates that RANI has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.36, RANI is doing good in the industry, outperforming 75.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.36 | ||
| Quick Ratio | 6.36 |
3. Growth
3.1 Past
RANI shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.91%.
EPS 1Y (TTM)-3.91%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
RANI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.95% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.11%
EPS Next 2Y22.33%
EPS Next 3Y17.92%
EPS Next 5Y25.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.
Also next year RANI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RANI's earnings are expected to grow with 17.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.33%
EPS Next 3Y17.92%
5. Dividend
5.1 Amount
RANI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RANI THERAPEUTICS HOLDINGS-A
NASDAQ:RANI (5/1/2024, 3:04:49 PM)
6.37
-0.01 (-0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap319.52M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.65% | ||
| ROE | -264.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.9 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.36 | ||
| Quick Ratio | 6.36 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-3.91%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37.11%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y